Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients

British Journal of Haematology

Volumn 141, Issue 5, 2008, Pages 587-597

  Prandoni, Paolo ^a   Samama, Michel M ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b HÔTEL DIEU   (France)

Author keywords

Anticoagulation; Cancer; Prevention; Thrombophilia; Venous thromboembolism

Indexed keywords

DALTEPARIN; DEXAMETHASONE; ENOXAPARIN; EXEMESTANE; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN; THALIDOMIDE; WARFARIN;

ANTICOAGULATION; BLEEDING; CANCER PATIENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FATALITY; HOSPITAL PATIENT; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT DURATION; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HOSPITALIZATION; HUMANS; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 43449116937     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07089.x     Document Type: Review

References (98)

1. Ageno, W.L., Squizzato, A., Garcia, D. Imberti, D. (2006) Epidemiology and risk factors of venous thromboembolism. Seminars in Thrombosis and Hemostasis, 32, 651 658.
2. Alikhan, R., Cohen, A.T., Combe, S., Samama, M.M., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Olsson, C.G. Turpie, A.G. (2004) Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine, 164, 963 968.
3. Altinbas, M., Coskun, H.S., Er, O., Ozkan, M., Eser, B., Unal, A., Cetin, M. Soyuer, S. (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis, 2, 1266 1271.
4. Anderson, F.A. Spencer, F.A. (2003) Risk factors for venous thromboembolism. Circulation, 107 (Suppl. 1 9 16.
5. Anderson, F.A., Wheeler, H.B., Goldberg, R.J., Hosmer, D.W. Forcier, A. (1992) The prevalence of risk factors for venous thromboembolism among hospital patients. Archives of Internal Medicine, 152, 1660 1664.
6. Arya, R., Paneesha, S., McManus, A., Parson, N., Scriven, B., Farren, T., Nokes, T., O'Shaughnessy, D. Rose, P. (2007) Derivation and validation of a prediction tool for venous thromboembolism: a VERITY registry study. Blood, 110, 214a.
7. Baron, J.A., Gridley, G., Weiderpass, E., Nyren, G. Linet, M. (1998) Venous thromboembolism and cancer. Lancet, 351, 1077 1080.
8. Bergmann, J.F. Caulin, C. (1996) Heparin prophylaxis and bed ridden patients. Lancet, 348, 205 206.
9. Bergmann, J.F. Kher, A. (2005) Venous thromboembolism in the medically ill patient: a call to action. International Journal of Clinical Practice, 59, 555 561.
10. Bern, M.M., Lokich, J.J., Wallach, S.R., Bothe, A., Benotti, P.N., Arkin, C.F., Greco, F.A., Huberman, M. Moore, C. (1990) Very low dose of warfarin can prevent thrombosis in central venous catheters. A prospective trial. Annals of Internal Medicine, 112, 423 428.
11. Blom, J.W., Doggen, C.J., Osanto, S. Rosendaal, F.R. (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 293, 715 722.
12. Boccaccio, C., Sabatino, G., Medico, E., Girolami, F., Follenzi, A., Reato, G., Sottile, A., Naldini, L. Comoglio, P.M.T. (2005) The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature, 434, 396 400.
13. Bosson, J.L. Labarère, J. (2006) Determining indications for care common to competing guidelines by using classification tree analysis: application to the prevention of venous thromboembolism in medical inpatients. Medical Decision Making, 26, 63 75.
14. Chew, H.K., Wun, T., Harvey, D.J., Zhou, H. White, R.H. (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Archives of Internal Medicine, 166, 458 464.
15. Chew, H.K., Wun, T., Harvey, D.J., Zhou, H. White, R.H. (2007) Incidence of venous thromboembolism and the impact on survival in breast cancer patients. Journal of Clinical Oncology, 25, 70 76.
16. Chopard, P., Dorffler-Melly, J., Hess, U., Wuillemin, W.A., Hayoz, D., Gallino, A., Bachli, E.B., Canova, C.R., Isenegger, J., Rubino, R. Bounameaux, H. (2005) Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. Journal of Internal Medicine, 257, 352 357.
17. Cohen, A.T., Alikhan, R., Arcelus, J.I., Bergmann, J.F., Haas, S., Merli, G.J., Spyropoulos, A.C., Tapson, V.F. Turpie, A.G. (2005) Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thrombosis and Haemostasis, 94, 750 759.
18. Cohen, A.T., Davidson, B.L., Gallus, A.S., Lassen, M.R., Prins, M.H., Tomkowski, W., Turpie, A.G., Egberts, J.F. Lensing, A.W. (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. British Medical Journal, 332, 325 329.
19. Cohen, A.T., Tapson, V.F., Bergmann, J.F., Goldhaber, S.Z., Kakkar, A.K., Deslandes, B., Huang, W., Zayaruzny, M., Emery, L., Anderson, F.A. Jr. ENDORSE Investigators (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet, 371, 361 362.
20. Colaizzo, D., Amitrano, L., Tiscia, G.L., Scenna, G., Grandone, E., Guardascione, M.A., Brancaccio, V. Margaglione, M. (2007) The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. Journal of Thrombosis and Haemostasis, 5, 55 61.
21. Coombes, R.C., Hall, E., Gibson, L.J., Paridaens, R., Jassem, J., Delozier, T., Jones, S.E., Alvarez, I., Bertelli, G., Ortmann, O., Coates, A.S., Bajetta, E., Dodwell, D., Coleman, R.E., Fallowfield, L.J., Mickiewicz, E., Andersen, J., Lonning, P.E., Cocconi, G., Stewart, A., Stuart, N., Snowdon, C.F., Carpentieri, M., Massimini, G., Bliss, J.M. van de Velde, C. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350, 1081 1092.
22. Couban, S., Goodyear, M., Burnell, M., Dolan, S., Wasi, P., Barnes, D., Macleod, D., Burton, E., Andreou, P. Anderson, D.R. (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. Journal of Clinical Oncology, 23, 4063 4069.
23. Deitcher, S.R. Gomes, M.P.V. (2004) The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma. Cancer, 101, 439 449.
24. Dentali, F., Douketis, J.D., Gianni, M., Lim, W. Crowther, M.A. (2007) Meta- analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Annals of Internal Medicine, 146, 278 288.
25. Douketis, J.D., Gu, C.S., Schulman, S., Ghirarduzzi, A., Pengo, V. Prandoni, P. (2007) The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Annals of Internal Medicine, 147, 766 774.
26. Francis, C.W. (2007) Prophylaxis for thromboembolism in hospitalized medical patients. New England Journal of Medicine, 356, 1438 1444.
27. Franco, R.F. Reitsma, O.H. (2001) Genetic risk factors of venous thrombosis. Human Genetics, 109, 369 344.
28. Gaitini, D., Beck-Razi, N., Haim, N. Brenner, B. (2006) Prevalence of upper extremity deep venous thrombosis diagnosed by color doppler duplex sonography in cancer patients with central venous catheters. Journal of Ultrasound in Medicine, 25, 1297 1303.
29. Gallus, A.S., Hirsh, J., Tutle, R.J., Trebilcock, R., O'Brien, S.E., Carroll, J.J., Minden, J.H. Hudecki, S.M. (1973) Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine, 288, 545 551.
30. Gardlund, B. (1996) Randomised controlled trial of low dose heparin prevention of fatal pulmonary embolism in patients with infectious disease. The heparin prophylaxis Study group. Lancet, 347, 1357 1361.
31. Geerts, W.H., Pineo, G.F., Heit, J.A., Bergqvist, D., Lassen, M.R., Colwell, C.W. Ray, J.G. (2004) Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 126, 338S 400S.
32. Goldhaber, S.Z. Tapson, V.F. (2004) A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. American Journal of Cardiology, 93, 259 262.
33. Haas, S.K., Hach-Wunderle, V., Mader, F.H., Ruster, K. Paar, W.D. (2007) An evaluation of venous thromboembolic risk in acutely ill medical patients immobilized at home: the AT-HOME Study. Clinical and Applied Thrombosis/Hemostasis, 277, 7 13.
34. Halkin, H., Goldberg, J., Modan, M. Modan, B. (1982) Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Annals of Internal Medicine, 96, 561 565.
35. Hansson, P.O., Welin, L., Tibblin, G. Eriksson, H. (1997) Deep vein thrombosis and pulmonary embolism in the general population. Archives of Internal Medicine, 157, 1665 1670.
36. Heit, J.A. (2006) Epidemiology of venous thromboembolism. In : Hemostasis and Thrombosis (ed. by R.W. Colman, V.J. Marder, A.W. Clowes, J.N. Georges S.Z. Golsdhaber 5th edn, pp. 1227 1234. Lippincott Williams and Wilkins Editors, Philadelphia, PA.
37. Heit, J.A., Silverstein, M.D., Mohr, D.N., Petterson, T.M., O'Fallon, W.M. Melton, L.J. (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Archives of Internal Medicine, 106, 809 815.
38. Heit, J.A., O'Fallon, W.M., Petterson, T.M., Lohse, C.M., Silverstein, M.D., Mohr, D.N. Melton, L.J. (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Archives of Internal Medicine, 162, 1245 1248.
39. Hull, R.D., Schellong, S.M., Tapson, V.F., Monreal, M., Samama, M.M., Turpie, A.G. Yusen, R.D. (2007) Late breaking clinical trial: extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced morbility: the exclaim study. Journal of Thrombosis and Haemostasis, 5 (Suppl. O-S-001.
40. Kahn, S.R., Panju, A., Geerts, W., Pineo, G.F., Desjardins, L., Turpie, A.G., Glezer, S., Thabane, L. Sebaldt, R.J. (2007) Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thrombosis Research, 119, 145 155.
41. Kakkar, A.K., Levine, M., Pinedo, H.M., Wolff, R. Wong, J. (2003) Venous thrombosis in cancer patients: insights from a frontline survey. The Oncologist, 8, 381 388.
42. Kakkar, A.K., Levine, M.N., Kadziola, Z., Lemoine, N.R., Low, V., Patel, H.K., Rustin, G., Thomas, M., Quigley, M. Williamson, R.C. (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer. Journal of Clinical Oncology, 22, 1944 1948.
43. Kanaan, A.O., Silva, M.A., Donovan, J.L., Roy, T. Al-Homsi, S. (2007) Meta-analysis of venous thromboembolism prophylaxis in medically ill patients. Clinical Therapeutics, 11, 2395 2405.
44. Karthaus, M., Kretzschmar, A., Kroning, H., Biakhov, M., Irwin, D., Marschner, N., Slabber, C., Fountzilas, G., Garin, A., Abecasis, N.G., Baronius, W., Steger, G.G., Sudhoff, T., Giorgetti, C. Reichardt, P. (2006) Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double- blind, placebo-controlled phase III trial. Annals of Oncology, 17, 289 296.
45. Khorana, A.A., Kuderer, N.M., Culkova, E., Lyman, G.H. Francis, C.W. (2008) Development and validation of a predictive model for chemotherapy- associated thrombosis. Blood Epub ahead of print Lyman, G.H. (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer, 104, 2822 2829.
46. Khorana, A.A., Francis, C.W., Culakova, E., Kuderer, N.M. Lyman, G.H. (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis, 5, 632 634.
47. King, C.S., Holley, A.B., Jackson, J.L., Shorr, A.F. Moores, L.K. (2007) Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest, 131, 507 516.
48. Kittur, J., Knudson, R.A., Lasho, T.L., Finke, C.M., Gangat, N., Wolanskyj, A.P., Li, C.Y., Wu, W., Ketterling, R.P., Pardanani, A. Tefferi, A. (2007) Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer, 109, 2279 2284.
49. Kleber, F.X., Witt, C., Vogel, G., Koppenhagen, K., Schomaker, U. Flosbach, C.W. (2003) Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal, 145, 614 621.
50. Klerk, C.P., Smorenburg, S.M., Otten, H.M., Lensing, A.W.W., Prins, M.H., Piovella, F., Prandoni, P., Bos, M.M., Richel, D.J., van Tienhoven, G. Buller, H.R. (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology, 23, 2130 2135.
51. Kucher, N., Koo, S., Quiroz, R., Cooper, J.M., Paterno, M.D., Soukonnikov, B. Goldhaber, S.Z. (2005) Electronic alerts to prevent venous thromboembolism among hospitalized patients. New England Journal of Medicine, 352, 969 977.
52. Lazo-Langner, A., Goss, G.D., Spaans, J.N. Rodger, M.A. (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. Journal of Thrombosis and Haemostasis, 5, 729 737.
53. Lee, A.Y., Rickles, F.R., Julian, J.A., Gent, M., Baker, R.I., Bowden, C., Kakkar, A.K., Prins, M. Levine, M.N. (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology, 23, 2123 2129.
54. Lee, A.Y., Levine, M.N., Butler, G., Webb, C., Costantini, L., Gu, C. Julian, J.A. (2006) Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. Journal of Clinical Oncology, 24, 1404 1408.
55. Leizorovicz, A. Mismetti, P. (2004) Preventing venous thromboembolism in medical patients. Circulation, 110, IV13 19.
56. Leizorovicz, A., Cohen, A.T., Turpie, A.G., Olsson, C.G., Vaitkus, P.T. Goldhaber, S.Z. (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation, 110, 874 879.
57. Levitan, N., Dowlati, A., Remick, S.C., Tahsildar, H.I., Sivinski, L.D., Beyth, R. Rimm, A.A. (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore), 78, 285 291.
58. Lyman, G.H., Khorana, A.A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N.M., Levine, M.N., Liebman, H., Mendelson, D., Raskob, G., Somerfield, M.R., Thodiyil, P., Trent, D. Francis, C.W. (2007) American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. Journal of Clinical Oncology, 25, 5490 5505.
59. Mahe, I., Bergmann, J.F., d'Azemar, P., Vaissie, J.J. Caulin, C. (2005) Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. European Journal of Clinical Pharmacology, 61, 347 351.
60. Miller, G.J., Bauer, K.A., Howarth, D.J., Cooper, J.A., Humphries, S.E. Rosenberg, R.D. (2004) Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. Journal of Thrombosis and Haemostasis, 2, 2107 2114.
61. Mismetti, P., Laporte-Simitsidis, S., Tardy, B., Cucherat, M., Buchmuller, A., Juillard-Delsart, D. Decousus, H. (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thrombosis and Haemostasis, 83, 14 19.
62. Monreal, M., Alastrue, A., Rull, M., Mira, X., Muxart, J., Rosell, R. Abad, A. (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices- prophylaxis with a low molecular weight heparin (fragmin). Thrombosis and Haemostasis, 75, 251 253.
63. Murchison, J.T., Wylie, L. Stockton, D.L. (2004) Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. British Journal of Cancer, 91, 92 95.
64. Naess, I.A., Christiansen, S.C., Romundstad, P., Cannegieter, S.C., Rosendaal, F.R. Hammerstrom, J. (2007) Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis, 5, 692 699.
65. Nicolaides, A.N., Fareed, J., Kakkar, A.K., Breddin, H.K., Goldhaber, S.Z., Hull, R., Kakkar, V.V., Michiels, J.J., Myers, K., Samama, M., Sasahara, A. Kalodiki, E. (2006) Prevention and treatment of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence. International Angiology, 25, 101 161.
66. Niers, T.M., Di Nisio, M., Klerk, C.P., Baarslag, H.J., Büller, H.R. Biemond, B.J.J. (2007) Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. Thrombosis and Haemostasis, 5, 1878 1882.
67. Nordstrom, M., Lindblad, B., Berqvist, D. Kjelstrom, T. (1992) A prospective study of the incidence of deep-vein thrombosis within a defined urban population. Journal of Internal Medicine, 232, 155 160.
68. Oger, E. (2000) Incidence of venous thromboembolism: a community-based study in Western France. Thrombosis and Haemostasis, 83, 657 660.
69. Prandoni, P., Falanga, A. Piccioli, A. (2005) Cancer and venous thromboembolism. Lancet Oncology, 6, 401 410.
70. Prichard, K.I., Paterson, A.H.G., Paul, N.A., Zee, B., Fine, S. Pater, J. (1996) Increased thromboembolic complication with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. Journal of Clinical Oncology, 14, 2731 2737.
71. Primignani, M., Barosi, G., Bergamaschi, G., Gianello, U., Fabris, F., Reati, R., Dell'Era, A., Bucciarelli, P. Mannucci, P.M. (2006) Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vien thrombosis. Hepatology, 44, 1528 1534.
72. Quinlan, D.J., Eikelboom, J.W., Dahl, O.E., Eriksson, B.I., Sidhu, P.S. Hirsh, J. (2007) Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. Journal of Thrombosis and Haemostasis, 5, 1438 1443.
73. Rocha, A.T., Paiva, E.F., Lichtenstein, A., Milani, Jr., R., Cavalheiro-Filho, C. Maffei, F.H. (2007) Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vascular Health and Risk Management, 3, 533 553.
74. Rosendaal, F.R. (1997) Risk factors for venous thrombosis: prevalence, risk, and interaction. Seminars in Hematology, 34, 171 187.
75. Samama, M.M. Kleber, F.X. (2006) An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients. Thrombosis Journal, 4, 1 8.
76. Samama, M., Cohen, A.T., Darmon, J.Y., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Nguyen, H., Olsson, C.G., Turpie, A.G. Weisslinger, N.A. (1999) Comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine, 341, 793 800.
77. Samama, M.M., Dahl, O.E., Mismetti, P., Quinlan, D.J., Rosencher, N., Cornelis, M., de Vries, H., van Beusekom, I. Kahan, J.P. (2006) An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica, 91, 64 67.
78. Schulman, S. Lindmarker, P. (2000) Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. New England Journal of Medicine, 342, 1953 1958.
79. Shen, V.S. Pollak, E.W. (1980) Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? Southern Medicine, 73, 841 843.
80. Sherman, D.G., Albers, G.W., Bladin, C., Fieschi, C., Gabbai, A.A., Kase, C.S., O'Riordan, W. Pineo, G.F. (2007) The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomized comparison. Lancet, 369, 1347 1355.
81. Sideras, K., Schaefer, P.L., Okuno, S.H., Sloan, J.A., Kutteh, L., Fitch, T.R., Dakhil, S.R., Levitt, R., Alberts, S.R., Morton, R.F., Rowland, K.M., Novotny, P.J. Loprinzi, C.L. (2006) Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings, 81, 758 767.
82. Själander, A., Jansson, J.H., Bergqvist, D., Eriksson, H., Carlberg, B. Svensson, P. (2008) Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis. Journal of Internal Medicine, 263, 52 60.
83. Sorensen, H.T., Mellemkjaer, L., Steffensen, H., Olsen, J.H. Nielsen, G.L. (1998) The risk of a diagnosis of cancer after primary deep-venous thrombosis or pulmonary embolism. New England Journal of Medicine, 338, 1169 1173.
84. Sorensen, H.T., Pedersen, L., Mellemkjaer, L., Johnsen, S.P., Skriver, M.V., Olsen, J.H. Baron, J.A. (2005) The risk of a second cancer after hospitalisation for venous thromboembolism. British Journal of Cancer, 93, 838 841.
85. Spencer, F.A., Lessard, D., Emery, C., Reed, G. Goldberg, R.J. (2007) Venous thromboembolism in the outpatient setting. Archives of Internal Medicine, 167, 1471 1475.
86. Stein, P.D., Beemath, A., Meyers, F.A., Skaf, E., Sanchez, J. Olson, R.E. (2006) Incidence of venous thromboembolism in patients hospitalized with cancer. American Journal of Medicine, 119, 60 68.
87. Tagalakis, V., Tamim, H., Blostein, M., Collet, J.P., Hanley, J.A. Kahn, S.R. (2007) Use of warfarin and risk of urogenital cancer: a population- based, nested case-control study. Lancet Oncology, 8, 395 402.
88. Tapson, V.F., Decousus, H., Pini, M., Chong, B.H., Froehlich, J.B., Monreal, M., Spyropoulos, A.C., Merli, G.J., Zotz, R.B., Bergmann, J.F., Pavanello, R., Turpie, A.G., Nakamura, M., Piovella, F., Kakkar, A.K., Spencer, F.A., Fitzgerald, G. Anderson, F.A. (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest, 132, 936 945.
89. Tefferi, A. Elliott, M. (2007) Thrombosis in myeloproliferative disorders. Seminars in Thrombosis and Hemostasis, 33, 313 320.
90. Turpie, A.G. Norris, T.M. (2004) Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin. Thrombosis and Haemostasis, 92, 3 12.
91. Verso, M. Agnelli, G. (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. Journal of Clinical Oncology, 21, 3665 3675.
92. Verso, M., Agnelli, G., Bertoglio, S., Di Somma, F.C., Paoletti, F., Ageno, W., Bazzan, M., Parise, P., Quintavalla, R., Naglieri, E., Santoro, A., Imberti, D., Soraru, M. Mosca, S. (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. Journal of Clinical Oncology, 23, 4057 4062.
93. Wein, L., Wein, S., Haas, S.J., Shaw, J. Krum, H. (2007) Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Archives of Internal Medicine, 167, 1476 1486.
94. White, R.H. (2003) The epidemiology of venous thromboembolism. Circulation, 107 (Suppl. 1 4 8.
95. White, R.H., Chew, H.K., Zhou, H., Parikh-Patel, A., Harris, D., Harvey, D. Wun, T. (2005) Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Archives of Internal Medicine, 165, 1782 1787.
96. Wu, O., Robertson, L., Langhorne, P., Twaddle, S., Lowe, G.D., Clark, P., Greaves, M., Walker, I.D., Brenkel, I., Regan, L. Greer, I.A. (2005) Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. Thrombosis and Haemostasis, 94, 17 25.
97. Yale, S.H., Medlin, S.C., Liang, H., Peters, T., Glurich, I. Mazza, J.J. (2005) Risk assessment model for venothromboembolism in post-hospitalized patients. International Angiology, 24, 250 254.
98. Zakai, N.A., Wright, J. Cushman, M.J. (2004) Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. Thrombosis and Haemostasis, 2, 2156 2161.